High-throughput drug discovery: what can we expect from HTS?
about
Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteinsProtein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor DiscoveryAdvancing drug innovation for neglected diseases-criteria for lead progressionA survey of across-target bioactivity results of small molecules in PubChemAdvances in Nuclear Magnetic Resonance for Drug Discovery.Paradigm shift in toxicity testing and modeling.Chemical microarray: a new tool for drug screening and discovery.Preformulation studies on imexon.A kinase-focused compound collection: compilation and screening strategy.Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseasePre-fractionated microbial samples--the second generation natural products library at Wyeth.Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors.Recent trends and observations in the design of high-quality screening collections.Targeting metalloproteins by fragment-based lead discovery.Discovery of regulators of receptor internalization with high-throughput flow cytometry.Single-molecule force spectroscopy of G-protein-coupled receptors.The current state of drug discovery and a potential role for NMR metabolomics.Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for successRapid and quantitative measurement of metabolic stability without chromatography or mass spectrometryAdaptation of high-throughput screening in drug discovery-toxicological screening tests.The road map to oral bioavailability: an industrial perspective.Respirometric Screening Technology for ADME-Tox studies.Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions.Innovative lead discovery strategies for tropical diseases.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Fragment informatics and computational fragment-based drug design: an overview and update.Discovery of small molecule cancer drugs: successes, challenges and opportunities.Structure-based drug screening for G-protein-coupled receptorsIn silico fragment-based drug design.Weak-binding molecules are not drugs?-toward a systematic strategy for finding effective weak-binding drugs.Rapid two-step synthesis of drug-like polycyclic substances by sequential multi-catalysis cascade reactions.Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate.Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products.Putting small molecules in the lead.Hot Melt Extrusion: A Process Overview and Use in Manufacturing Solid Dispersions of Poorly Water-Soluble DrugsHigh-throughput structural characterisation of therapeutic protein targets
P2860
Q24649147-E191A18D-B0D8-42AF-85E8-B6A9557EBBDEQ26738763-BA96AF1A-7EED-4C89-8C61-A2175F5EE266Q28475996-E9D8E260-EC4E-455A-A7F4-89833A8A99EEQ28751797-C88B50EC-9506-4F3F-81D3-84262DE54B6BQ30387229-98BC6ED6-89D4-49F8-B728-6642B0F75440Q30455359-4C3A333E-4341-4B87-863E-ED54A960C74EQ30492821-FE3A108E-8B84-4CCE-B1BD-C6ACB3573CFFQ31051236-3D1A71E2-6C84-4865-AAE7-B3C0E0C7132DQ33252499-A85BE249-36BC-4D6A-9F37-47625BFB5CB2Q33292772-657CCC9C-72BC-4328-AC1B-F4AC4B6B8119Q33348503-47AA9AD8-5ABF-4220-B841-A57FCD5804AFQ33834499-8C2CDE31-F710-4730-A707-A161536375B2Q33893113-01A274B7-370C-48CC-A095-4029AC882E20Q33896509-EF2E583F-176F-49A4-9CDC-F888C55B650EQ34327895-5520BC9F-6656-43A8-B914-984247A9E287Q34782818-33B2D74C-A85F-4DEC-9173-86BA8828BAA8Q35072850-48B5C7D7-C374-4CFC-A58B-75C15210AC2AQ35096907-DE77280C-44E8-423C-B2AA-43A7A5B550A8Q35231752-B68B906B-10AD-467C-AE9E-8322CA7878F4Q35719340-7D4C4DBA-DEDA-476F-9760-1BE3A2AB05BDQ36543116-6937099B-FAC6-4703-82A5-BCEE3CA42D7CQ36546284-301D8C65-F5CC-4A61-8B2F-672A9EF98196Q36614773-9E23A7CF-C7E6-42AE-B7E0-57B50B345F36Q36642049-EE71E72D-6561-4440-A087-C73140AC1959Q36960535-A83B3776-BC15-4064-8A75-A1DA3D2AEEFBQ37995087-67297C04-C789-4B91-9F7C-45C69AADCA02Q37996113-E37D9B57-EF95-4D3C-A19F-6DED93E4DE1AQ38002626-5489F4CF-AAFB-43B9-9670-022FEB20834CQ38029118-06A1BEFA-B583-42FF-97AE-CF1B88B294B8Q38897226-814E3BD0-BEDB-42C1-87DA-4FEA9C8A0ABFQ43196985-FB673CB4-CB4C-47E8-9D2B-5D38CCC8ABC0Q44767781-AC500EFA-F512-45F8-87B2-DF760964B1BDQ46096405-2979B531-8E2E-4865-ACD4-126CFB83454AQ52935238-91A2F382-9953-465A-947A-B1C9DB278C3FQ57340445-5FFF67A7-1378-4D0C-80AD-C8D9C12DF0B9Q57937286-DC1E1E05-A4EA-46FF-9E7F-6FD6F542507E
P2860
High-throughput drug discovery: what can we expect from HTS?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
High-throughput drug discovery: what can we expect from HTS?
@ast
High-throughput drug discovery: what can we expect from HTS?
@en
type
label
High-throughput drug discovery: what can we expect from HTS?
@ast
High-throughput drug discovery: what can we expect from HTS?
@en
prefLabel
High-throughput drug discovery: what can we expect from HTS?
@ast
High-throughput drug discovery: what can we expect from HTS?
@en
P1433
P1476
High-throughput drug discovery: what can we expect from HTS?
@en
P2093
Andreas Sewing
Phillip Gribbon
P356
10.1016/S1359-6446(04)03275-1
P577
2005-01-01T00:00:00Z